Trish Shucoski Named BayCare’s Incoming Chief Nurse Executive

BayCare announced today that Patricia “Trish” Shucoski, DNP, MSN, RN, NEA-BC, will be its next Chief Nurse Executive (CNE), leading a corps of more than 10,550 nurses and nursing support staff when she assumes the role in December.

Shucoski is a nurse with nearly 20 years of experience as a health care leader and holds a doctorate in nursing practice. A Florida licensed nurse, she is currently BayCare’s vice president of customer access and operational excellence and is succeeding CNE Lisa Johnson, who is retiring after more than a 35-year career with BayCare.

“BayCare’s nurses and our patients deserve the very best in a leader and we are excited to have Trish take this role,” said CEO and President Stephanie Conners. “Her experience supporting patient care delivery will ensure that BayCare’s nurses remain at the forefront in the industry in best practice and compassionate care.”

Prior to joining BayCare, Shucoski worked for Jefferson Health in Philadelphia as its senior vice president for performance excellence and system integration. Before that, she worked as Cooper University Hospital’s associate vice president of patient care services for four years and its executive director of hospital-based services for three years. As a registered nurse in New Jersey and Pennsylvania, Trish worked for both Cancer Treatment Centers of America, where she was chief nurse, and Hahnemann University Hospital/Tenet Healthcare.

She earned a Doctor of Nursing practice/healthcare systems leadership from Chamberlain University; a Master of Science in nursing, leadership/nursing management from Drexel University, and a bachelor’s degree in nursing from Villanova University. Additionally, Trish holds two associate degrees, one from the State University of New York at Farmingdale (SUNY Farmingdale) in allied health and science/nursing and one in science from Nassau Community College.

Shucoski resides with her husband and two children in Largo. She will assume the CNE role on Dec. 11.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”